RECRUITING

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

Talk to us

Conditions

Amphetamine-Related Disordersmethamphetamine, stimulant, psilocybin, psychedelic, psychotherapy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.

Official Title

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

Quick Facts

Study Start:2022-07-07
Study Completion:2025-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04982796

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:25 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * United States military Veteran
  2. * Moderate to severe methamphetamine use disorder using the DSM-V diagnostic criteria
  3. * Desire to cease or reduce methamphetamine use
  1. * Have uncontrolled hypertension or clinically significant cardiovascular disease
  2. * History of seizure disorder in adulthood
  3. * CNS metastases or symptomatic central nervous system (CNS) infection
  4. * Poorly controlled diabetes mellitus
  5. * Taking certain medications that may interact with psilocybin
  6. * History of any primary persistent psychotic disorder, including schizophrenia, schizoaffective disorder, bipolar disorder with psychosis, major depressive disorder with psychosis, or schizophreniform disorder
  7. * History of bipolar I disorder
  8. * Current eating disorder with active purging
  9. * History of hallucinogen use disorder
  10. * Pregnant or breast feeding

Contacts and Locations

Study Contact

Bianca Watt, MSc
CONTACT
(503) 781-1205
Bianca.Watt@va.gov
Kevin Rothstein-Kightly, MS
CONTACT
(360) 450-9349
Kevin.Rothstein-Kightly@va.gov

Principal Investigator

Chris Stauffer, MD
PRINCIPAL_INVESTIGATOR
Oregon Health and Science University

Study Locations (Sites)

Portland VA Health Care System
Vancouver, Washington, 98661
United States

Collaborators and Investigators

Sponsor: Portland VA Research Foundation, Inc

  • Chris Stauffer, MD, PRINCIPAL_INVESTIGATOR, Oregon Health and Science University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-07-07
Study Completion Date2025-04-30

Study Record Updates

Study Start Date2022-07-07
Study Completion Date2025-04-30

Terms related to this study

Keywords Provided by Researchers

  • methamphetamine, stimulant, psilocybin, psychedelic, psychotherapy

Additional Relevant MeSH Terms

  • Amphetamine-Related Disorders